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Background: Efficacy of recombinant adenovirus serotype 5 (rAd5) vaccine vectors for human immunodeficiency
virus type 1 (HIV-1) and other pathogens have been shown to be limited by high titers of pre-existing Ad5
neutralizing antibodies (NAbs) in the developing world.
Results: Using a secreted embryonic alkaline phosphatase (SEAP) neutralization assay, 50% serum neutralization
titers against rAd2 and rAd5 vectors were measured in samples from 274 infants and young children in northeast
China. The pediatric population was found to be 59.6% and 43.3% seropositive for rAd2 and rAd5, respectively. Of
all participants, 44.9% had moderate and high (> 200) and 25.6% had high (>1000) Ad2 NAb titers, compared with
the corresponding rates of 26.6% and 9.3% against Ad5. Marked age-dependent increases in NAb titers to both Ad
serotypes were observed across five age groups, with the exception of infants in the 0-6-month group commonly
having relatively high titers due to pre-existing maternal antibodies.
Conclusions: Our data suggest that Ad-based therapies may be suitible for children in the 7-12-month age range
in this region.
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Adenoviruses (Ad) are non-enveloped, double-stranded
DNA viruses of the Adenoviridae family which infect a
wide range of vertebrate hosts. There are over 50 dif-
ferent serotypes of Ads of the genus Mastadenovirus
known to infect humans and are divided into six sub-
groups, A to F [1]. Adenoviral vectors have been used
for a variety of vaccine applications against various can-
cers and infectious diseases. Unfortunately, a majority of
the human population has been infected by wild-type
Ads in childhood, and often these individuals harbor
pre-existing immunity to a number of common Ad se-
rotypes (i.e., serotypes 2, 4, 5 and 7) [2,3]. The clinical
application of these Ad serotypes in construction of* Correspondence: weikong@jlu.edu.cn; xianghui@jlu.edu.cn
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reproduction in any medium, provided the orvaccines may be seriously hampered due to neutralizing
antibodies (NAbs) to these vectors [4]. Baseline levels of
Ad5 NAbs have been shown to suppress the immuno-
genicity of rAd5 vector-based vaccines for HIV-1 both in
preclinical studies [5] and in clinical trials [6].
The seroprevalence of Ad serotypes commonly used in
vaccine clinical trials, such as Ad2 and Ad5 from sub-
group C, were found to be higher than other types in
Europe, Asia and the United States [7]. An international
epidemiological study on Ad type-5, -6, -26 and −36
showed that the overall proportion of anti-Ad5 seroposi-
tive individuals was 85.2%, and Ad5 NAb titers varied by
geographic location, appearing to be higher in non-US
and non-European settings [8]. In that study, Asian
(Thai) participants had the highest Ad5 NAb titers; how-
ever, samples from China were not included. Meanwhile,
one report indicated that Ad5 NAb titers were low in
young children in sub-Saharan Africa [9]. Appaiahgari
et al. showed in an experimental mouse model that low
levels of Ad5 NAbs had no effect on the protective effi-
cacy of an Ad5-derived recombinant virus expressingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Ad2, Ad5 and Ad2/Ad5 (Ad2 + Ad5) NAb titers in
serum samples of all children stratified by titers: <18
(negative), 18–200 (low), 201–1000 (moderate) and >1000
(high).
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These observations raise the possibility of using Ad5-
derived recombinant vaccines for immunization in popu-
lations with low Ad5 NAb levels.
A recent study of Ad5 in Guangzhou (capital city of
Guangdong province in southern China) demonstrated
that 77.4% of the 200 subjects evaluated were seropo-
sitive, showing an intermediate prevalence of Ad5 in-
fection in southern China [11]. However, our prior
epidemiological study of Ad5 NAbs showed that areas in
southern China may have a higher seroprevalence of
Ad5 than in other regions [12]. The objective of this
current study was to determine the prevalence of NAbs
against both Ad2 and Ad5 in pediatric populations in
northeast China. The serum samples of children from 1
day to 12 years of age were divided into different age
groups to monitor their antibody titers. The finding of
age-dependent Ad NAb titers in this study may have
implications for the clinical application of Ad-based vac-
cines and gene therapy in China.
Materials and methods
Human serum samples
A total of 274 serum samples were obtained from
healthy children from 1 day to 12 years of age, living in
Changchun city, Jilin (province in northeast China). All
of the samples were collected randomly from February
to October in 2011. Informed consent was obtained
from the legal guardians of all participants, and the
serum samples utilized in Ad neutralization assays were
approved by the Human Ethical Committee Institutional
Review Board of Jilin University, Jilin, China. All human
sera were inactivated at 56°C for 60 min prior to testing.
Virus neutralization assays
The Ad2-SEAP and Ad5-SEAP vector was constructed
as previously described [7,13]. In these E3 deletion
vectors, the E1 region was replaced by the SEAP gene.
Ad-specific NAb titers were assessed using a secreted
embryonic alkaline phosphatase (SEAP) quantitation
assay [14]. Briefly, HEK293 cells were infected with Ad2-
SEAP or Ad5-SEAP. Concurrently, 4 × 106 viral particles
(vp) of Ad-SEAP were incubated for 1 h at 37°C either
alone (set as 100% SEAP activity) or with five serial dilu-
tions of serum in DMEM with 10% fetal bovine serum
(FBS) before infection. The final serum dilutions were
1:18, 1:72, 1:288, 1:1152 and 1:4608, and each serum
sample was tested in duplicate. After incubation at 37°C
for 24 h, supernatants were collected and assayed for
SEAP activity using the chemiluminescent substrate
CSPD (Roche, Basel, Switzerland) according to the man-
ufacturer’s instructions. Luminescence intensity was
measured using a Victor 1420 Multilabel counter (Perkin
Elmer, Wellesley, MA, USA). The neutralization titerwas defined as the inverse of the serum dilution at
which SEAP activity was reduced by 50% of that with
the virus alone.
Statistical analysis
Logistic regression was used to calculate the odds ratios
(OR) and 95% confidence intervals (CI) to analyze fac-
tors associated with moderate and high Ad2 and Ad5
NAb titers (>200) in all samples. A binary variable was
established to represent Ad NAb titers >200 or low/
negative titers ≤200 among each group of samples. Uni-
variate logistic regression analysis identified variables
associated with moderate and high NAb titers at the
P < 0.05 level of significance. Standard deviation and/or
percentages were analyzed by SPSS 16.0 using Chi-square
and t tests.
Results
We first evaluated the prevalence of NAbs against Ad2-
SEAP and Ad5-SEAP in sera taken from 274 children
from 1 day to 12 years of age. To determine the relative
differences in titers in different populations, Ad NAb
titers were divided into subgroups, similar to those
reported for other Ad seroprevalence studies [15]. As
shown in Figure 1, Ad2 and Ad5 seroprevalence rates
were 59.6% and 43.3% in all test populations, respec-
tively. It was found that 44.9% of participants had mode-
rate and high Ad2 NAb titers (> 200) and 25.6% had
very high titers (> 1000), compared with the correspon-
ding rates of 26.6% and 9.3% against Ad5. The results
also showed that over 60% of children in northeast
China were positive for NAbs (titer > 18) against either
the Ad2 or Ad5 serotype, and 51.0% had moderate
and high levels of Ad2/Ad5 NAb titers. To evaluate the
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Ad5 in infants (0–24 months old) and children (3–12
years old), frequency histograms were drawn to illustrate
the impact of age on Ad2 and Ad5 infection. Serum
NAb levels are shown for five separate age groups in
Figure 2. It was found that the percentages of individuals
seronegative to both Ad serotypes increased with in-
creasing age, with the exception of the 0-6-month-old
group showing a larger portion of low (18–200) and
moderate (201–1000) titers than other groups. In this
youngest group, 74.6% and 77.2% were seropositive to
Ad2 and Ad5 NAbs, respectively. It also appeared that
the 7-12-month-old group had the lowest percentages
(Ad2, 5.4%; Ad5, 11.2%) of baseline Ad NAb titers, and
the percentages of baseline titers increased with increa-
sing age from this age group up to the 7-12-year-old
group. Additional interesting findings were that serum
samples in over 50% of the 7 newborn infant (<3 days)
had baseline Ad2 and Ad5 NAb titers, and the me-
dian Ad2 and Ad5 NAb titers were 368 and 288 in the
0-6-month-old group, respectively (Figure 3).
Univariate analyses of factors associated with moderate
and high Ad2 and Ad5 titers are shown in Table 1. Un-
adjusted regression suggested a trend where moderate
and high Ad2 titers increased along with age when the
children over the age of 12 months. Ad5 titers displayed
a similar valley-like trend, and these associations were
weak and not statistically significant. In addition, no appa-
rent differences in Ad2 or Ad5 seroprevalence between
genders were found in all pediatric populations.
Discussion
The high prevalence of human anti-Ad5 Abs, especially
in sub-Saharan Africa, suggests that administration of
Ad5-based vectors will likely lead both to antibody neu-
tralization and a rapid, exacerbated cellular immune re-
sponse in many individuals [16]. The practical scope
of this problem was illustrated by the HIV-STEP trial,
the first clinical trial aimed towards eliciting vaccine-Figure 2 Seroprevalence of Ad2 and Ad5 in different age groups. Num
(13–24 M), 97 (3–6 Y), and 48 (7–12 Y). M = months; Y = years.induced cellular HIV immunity in humans. In partici-
pants with high initial anti-Ad5 antibody titers, the vac-
cine appeared to have increased HIV infection [17]. As
HIV vaccine trials are now underway in children [18], it
is important to determine at what age Ad NAbs become
more prevalent. However, few studies on the seropreva-
lence of NAbs to Ad5 or other serotypes in pediatric
populations, especially infants, have been published to
date. Previous studies indicated that Ad5 NAb titers are
low in young children, and immunity to Ad5 vector is
age-dependent [9,14]. However, a recent international
epidemiological study of several Ad types reported a
high Ad5 seroprevalence (65.9%) and correspondingly
high-titer NAbs (titers > 1000) (43.2%) in children of
South Africa [19]. In China, only one prior study in
Guangdong demonstrated that 77.9% (28/36) of the
participants were seropositive for Ad5 NAbs [11]. Our
data showed that the seroprevalence of Ad5 NAbs in
northeast China was apparently lower than that that
in southern China, especially for the high-titer NAbs
(18.8% vs. 30.6%), indicating that the anti-Ad5 titers
may vary by geographic location.
In all 6 subgroups of Ad serotypes, Ad1, 2, 5 and 6
from subgroup C have been demonstrated to be more
seroprevalent than serotypes in other subgroups [7,8].
Our current observations of the seroprevalence of Ad2
NAbs in China confirmed and extended the findings of
prior studies. Pre-existing immunity to Ad can include
both neutralizing antibodies, as well as Ad-specific T cell
responses, as recent studies have highlighted a critical
role for CD8+ T cells in pre-existing anti-Ad immunity
[20-22]. It should also be noted that the magnitude and
phenotype of cellular immune responses elicited by Ads
may be cross-reactive. Considering the possibility of
cross-reactivity within the same subgroup which may
lead to a high seroprevalence of Ad even in infants or
young children, our analysis of Ad2/5 NAb titers sug-
gests that the approach of combining different Ad vac-
cine vectors for heterologous priming or constructingber of serum samples in each age group: 50 (0–6 M), 37 (7–12 M), 42
Figure 3 Ad2 and Ad5 NAb titers in serum samples from 7 individual newborn infants (< 3 days) (bars, median titers) and
50 0-6-month-old infants (box-and-whisker plots).
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will need to be carefully designed.
High titer of Ad5 NAbs have been shown to suppress
the immunogenicity of rAd5 vector-based vaccines for
HIV-1 in both preclinical studies [5,23] and clinical trials
[6,24,25]. In this study, significant differences in Ad anti-
body titers were monitored by performing univariate
analysis of the association of age with moderate and
high Ad2 and Ad5 titers. The levels of moderate and
high Ad2 and Ad5 NAbs in children showed an age-
dependent increase along with Ad-specific immunity,
with 7-12-month-old infants having the lowest levels of
anti-Ad immunity. We also found that samples from the
youngest infants (0–6 months), even from seven new-
born infants (< 3 days), had moderate and high titers of
Ad2 and Ad5 NAbs. These results are consistent with
prior studies showing that the pediatric population har-
bors anti-Ad titers at birth due to passively acquired ma-
ternal Abs which substantial decline by 6 months of age
[8,9] but then drastically increase again after 18 monthsTable 1 Unadjusted and adjusted odds of moderate and high
Population Ad2 NAb Titers >200






0-6 mo 25 (50.00, 20.33) 1.00
7-12 mo 2 (5.41, 1.63) 0.06 (0.01, 0.26) 0.07 (0.02, 0
13-24 mo 21 (50.00, 17.07) 1.00 (0.44, 2.27) 1.23 (0.64, 2
3-6 yr 45 (46.39, 36.58) 0.87 (0.44, 1.71) 1.06 (0.67, 1
7-12 yr 30 (62.50, 24.39) 1.67 (0.74, 3.73) 2.05 (1.09, 3
Sex
Male 58 (39.73, 47.15) 1.00
Female 65 (50.78, 52.85) 1.56 (0.97, 2.53)
OR = odds ratio; CI = confidence interval. mo = months; yr = years.
a Data as a percentage of overall samples in each age or sex group.
b Data as a percentage of overall data (Ad NAb titers >200).of age [26]. In the present study, NAbs for the Ad2 sero-
type were shown to increase markedly even after 12
months of age (Figure 2 and Table 1). These results indi-
cate that adenovirus-based therapies may not be suitable
for children above 12 months and below 6 months of
age. These findings also suggest that before using Ad-
based vaccines in a specific region, a thorough sero-
logical survey of NAbs for different Ad types in pediatric
populations should be carried out, since pre-existing
immunity may result in adverse inflammatory respon-
ses [19].
In summary, the seroepidemiological assessment con-
ducted in this study revealed an interesting age-
dependent association of anti-Ad2 and Ad5 NAbs in
pediatric populations in northeast China, Thus, poten-
tially high NAb titers to Ad in newborns or older chil-
dren (>12 months) should be taken into consideration
when designing Ad-based vaccines, while children of the
7-12-month age range with relatively low Ad-specific
immuity may benefit the most from such vaccines.Ad2 and Ad5 NAb titers in children of northeast China
Ad5 NAb Titers >200





20 (40.00, 27.03) 1.00
.30) 4 (10.81, 5.40) 0.18 (0.06, 0.59) 0.33 (0.11, 0.96)
.35) 8 (19.05, 10.81) 0.35 (0.14, 0.92) 0.64 (0.28, 1.44)
.69) 26 (26.80, 35.14) 0.55 (0.27, 1.13) 0.99 (0.59, 1.67)
. 85) 16 (33.33, 21.62) 0.75 (0.33, 1.71) 1.35 (0.70, 2.61)
40 (27.40, 54.05) 1.00
34 (26.56, 45.95) 0.96 (0.56, 1.64)
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